Friday, October 16, 2026
ExploreSearch
Via News

Markets & Regulation

2 articles

U.S. Tax Rule Powers QQQI's Edge—Washington Could Pull It Without Warning

U.S. Tax Rule Powers QQQI's Edge—Washington Could Pull It Without Warning

QQQI's after-tax yield advantage rests entirely on a decades-old U.S. tax provision that regulators could revoke at any time. Risk analysts rate the consequences of reclassification as catastrophic, though the probability remains low. Global investors holding the fund carry an asymmetric exposure: stable gains today, sudden structural change possible tomorrow.

LM Salvado•
Lufax Drops 14%, Faces Class Action After PwC Quits Over Hidden Transactions

Lufax Drops 14%, Faces Class Action After PwC Quits Over Hidden Transactions

Chinese fintech Lufax lost 14% of its NYSE-listed stock value in January 2025 after PwC resigned, citing undisclosed related-party transactions for 2022–2023. A securities class action followed in April 2026, filed by Hagens Berman. The case is now a reference point for global investors assessing audit risk in cross-listed Chinese companies.

LM Salvado•
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,377 source documents archived
Query this data → isubstrate.com